search
Back to results

Effect of Collagen/Vitamin C in Jumper's Knee; a RCT (Jumpfood)

Primary Purpose

Patellar Tendinopathy

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Collagen + vitamin C
Sponsored by
Gelderse Vallei Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patellar Tendinopathy focused on measuring collagen, progressive tendon loading therapy, gelatin, RCT

Eligibility Criteria

16 Years - 40 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 16 - 40 years old (the chosen age range will minimize chances of other conditions causing anterior knee pain such as osteoarthritis among patients above 40 years and osteochondrotic diseases like Sinding-Larsen-Johansson syndrome and Osgood-Schlatter disease among patients below the age of 16).
  • History of focal knee pain in patellar tendon or its patellar or tibial insertion in association with training and/or competition.
  • Current symptom duration of at least 12 weeks.
  • Sports participation at least once a week for at least one year.
  • Palpation tenderness to the corresponding painful area on the patellar tendon.
  • Focal patellar tendon pain during patellar tendon loading pain provocation test (single leg decline squat and/or single leg jump squat)
  • Victorian Institute of Sports Assessment (VISA-P) score < 80 out of 100 points.
  • Willingness to take (non-vegetarian) nutritional supplements.

Exclusion Criteria:

  • - Known presence of inflammatory joint diseases (e.g. spondylarthropathy, gout or rheumatoid arthritis) or familial hypercholesterolaemia.
  • Contraindications for MRI (pregnancy, metallic implants, etc.)
  • Daily use of drugs with a putative effect on the patellar tendon in the preceding year (e.g. fluoroquinolones and statins)
  • Knee surgery without a full completion of the rehabilitation program in the history of the index knee
  • Previous patellar tendon rupture of the index knee
  • Local injection therapy with corticosteroids, other drugs, blood, platelet rich plasma or stem cells in the preceding 12 months
  • Acute knee or patellar tendon injuries (other than PT)
  • Inability to perform the PTLE program
  • Participation in other concomitant treatment programs
  • Signs or symptoms of other coexisting knee pathology on physical examination (such as joint effusion and joint line tenderness) or additional diagnostics (Chondral lesion of the patella or trochlea on MRI or prepatellar bursitis on US).
  • Already using collagen supplementation

Sites / Locations

  • Gelderse Vallei HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Supplement + progressive tendon loading therapy

Placebo + progressive tendon loading therapy

Arm Description

The intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C, in comparison to a placebo supplement consisting of maltodextrin. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.

The placebo consists of maltodextrin. In comparison the intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.

Outcomes

Primary Outcome Measures

VISA-P Score
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
VISA-P Score
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
VISA-P Score
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
VISA-P Score
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
VISA-P Score
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up

Secondary Outcome Measures

Pain during functional tests
During several functional tests, pain will be measured on a visual analogue scale, with 0 meaning no pain and 10 meaning unbearable pain, at baseline, 12 weeks and 24 weeks of follow-up.
Pain during functional tests
During several functional tests, pain will be measured on a visual analogue scale, with 0 meaning no pain and 10 meaning unbearable pain, at baseline, 12 weeks and 24 weeks of follow-up.
Imaging methods
Several imaging methods will be performed to identify the physiological parameter tendon structure shown in percentages healthy and damaged cells, at baseline, 12 weeks and 24 weeks of follow-up.
Imaging methods
Several imaging methods will be performed to identify the physiological parameter tendon structure shown in percentages healthy and damaged cells, at baseline, 12 weeks and 24 weeks of follow-up.
Stiffness measurement
The physiological parameter stiffness of the tendon will be measured in N/m, at baseline, 12 weeks and 24 weeks of follow-up.
Stiffness measurement
The physiological parameter stiffness of the tendon will be measured in N/m, at baseline, 12 weeks and 24 weeks of follow-up.
Blood levels of amino acids
Concentration of amino acids in blood will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Blood levels of amino acids
Concentration of amino acids in blood will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Blood levels of inflammatory markers
Concentration in blood of the inflammatory markers BSE and CRP will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Blood levels of inflammatory markers
Concentration in blood of the inflammatory markers BSE and CRP will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Dietary habits
Dietary habits (nutritional intake) will be measured at the start and end of the intervention period using a diary.
Dietary habits
Dietary habits (nutritional intake) will be measured at the start and end of the intervention period using a diary.
Compliance
Data on the compliance with the exercise program and supplement intake, but also on training and competition load will be collected weekly using an online questionnaire

Full Information

First Posted
January 8, 2022
Last Updated
August 25, 2023
Sponsor
Gelderse Vallei Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05407194
Brief Title
Effect of Collagen/Vitamin C in Jumper's Knee; a RCT
Acronym
Jumpfood
Official Title
Additional Effect of Collagen/Vitamin C in Exercise Treatment for Patellar Tendinopathy (Jumper's Knee); a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2023 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Gelderse Vallei Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patellar tendinopathy (PT) is a tendon overuse injury with high prevalence rates in elite and recreational athletes. PT sometimes results in a prolonged absence from sport participation, hampering individuals to achieve their desired performance levels and to benefit from the health related effects of sports participation. Many treatment options are used but management of PT remains challenging. Current treatment involves progressive education, load management and tendon loading exercises (PTLE). Recent studies have shown that nutrition can positively affect collagen synthesis in musculoskeletal tissues. A study showed that supplementing 15g of gelatine combined with 50mg of Vitamin C, 1 hour before loading exercises, resulted in an increase in whole body collagen synthesis and increased mechanics and collagen content of human engineered ligaments. However the effectiveness of oral supplementation of hydrolysed collagen in combination with vitamin C in athletes with PT has not been studied in a randomized controlled trial yet. Objective: The primary aim of this RCT is to evaluate whether the use of oral supplementation of hydrolysed collagen/vitamin C in addition to usual care (education, load management and PTLE) is superior to usual care and placebo on VISA-P score after 12, 24 and 52 weeks for athletes with PT. The secondary aim of this RCT is to evaluate whether the use of oral supplementation of hydrolysed collagen/vitamin C in addition to usual care (education, load management and PTLE) is superior to usual care and placebo on other clinical outcome parameters, functional tests and tendon structure after 12 and 24 weeks for athletes with PT.
Detailed Description
Rationale: Patellar tendinopathy (PT) is a tendon overuse injury with high prevalence rates in elite and recreational athletes. PT sometimes results in a prolonged absence from sport participation, hampering individuals to achieve their desired performance levels and to benefit from the health related effects of sports participation. Many treatment options are used but management of PT remains challenging. Current treatment involves progressive education, load management and tendon loading exercises (PTLE). Recent studies have shown that nutrition can positively affect collagen synthesis in musculoskeletal tissues. A study showed that supplementing 15g of gelatine combined with 50mg of Vitamin C, 1 hour before loading exercises, resulted in an increase in whole body collagen synthesis and increased mechanics and collagen content of human engineered ligaments. However the effectiveness of oral supplementation of hydrolysed collagen in combination with vitamin C in athletes with PT has not been studied in a randomized controlled trial yet. Objective: The primary aim of this RCT is to evaluate whether the use of oral supplementation of hydrolysed collagen/vitamin C in addition to usual care (education, load management and PTLE) is superior to usual care and placebo on VISA-P score after 12, 24 and 52 weeks for athletes with PT. The secondary aim of this RCT is to evaluate whether the use of oral supplementation of hydrolysed collagen/vitamin C in addition to usual care (education, load management and PTLE) is superior to usual care and placebo on other clinical outcome parameters, functional tests and tendon structure after 12 and 24 weeks for athletes with PT. Study design: The JUMPFOOD-study is a double blinded, 2-armed randomized placebo controlled trial which investigates the effectiveness of oral supplementation of hydrolysed collagen and vitamin C combined with progressive tendon loading exercise compared to only progressive tendon loading exercises in athletes with PT. Study population: Recreational, competitive and professional male and female athletes from different kinds of sports will be included. Inclusion criteria: age 16-40 years old; history of focal knee pain for at least 12 weeks localized in the region of the patellar tendon in association with training and competition; playing sports for at least once a week for at least one year; palpation tenderness to the corresponding painful area on the patellar tendon; Victorian Institute of Sports Assessment - Patella (VISA-P) score < 80 out of 100 points. Intervention: The intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C, in comparison to a placebo supplement consisting of maltodextrin. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement. Main study parameters/endpoints: The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up. Secondary outcomes will include: Pain during functional tests, advanced imaging methods and tendon structure and stiffness measurements (MRI, ultrasound, UTC, Myoton), blood levels of amino acids and inflammatory markers measured in blood, and dietary habits, that will all be measured at baseline, at 12 weeks and at 24 weeks of follow-up. In addition, data on the compliance with the exercise program and supplement intake, training and competition load will be collected weekly using an online questionnaire.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patellar Tendinopathy
Keywords
collagen, progressive tendon loading therapy, gelatin, RCT

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
RCT
Masking
Investigator
Masking Description
Supplement and placebo will be blinded for participants and researchers working on the study.
Allocation
Randomized
Enrollment
76 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Supplement + progressive tendon loading therapy
Arm Type
Experimental
Arm Description
The intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C, in comparison to a placebo supplement consisting of maltodextrin. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
Arm Title
Placebo + progressive tendon loading therapy
Arm Type
Placebo Comparator
Arm Description
The placebo consists of maltodextrin. In comparison the intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
Intervention Type
Dietary Supplement
Intervention Name(s)
Collagen + vitamin C
Intervention Description
Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
Primary Outcome Measure Information:
Title
VISA-P Score
Description
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
Time Frame
after 6 weeks follow-up
Title
VISA-P Score
Description
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
Time Frame
after 12 weeks follow-up
Title
VISA-P Score
Description
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
Time Frame
after 18 weeks follow-up
Title
VISA-P Score
Description
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
Time Frame
after 24 weeks follow-up
Title
VISA-P Score
Description
The primary outcome measure will be the change in the Dutch version of the VISA-P score. This simple, validated, reliable and injury-specific questionnaire scores the severity of patellar tendinopathy and is sensitive to small changes in symptoms. It was specifically designed for patellar tendinopathy, rating pain, symptoms, simple test of function and the ability to participate in tendon-loading sports [1]. A VISA-P score of 100 indicates no pain, maximum function and maximum ability to play sports. The score decreases with increasing severity of symptoms of PT. The VISA-P questionnaire will be self-administered at baseline, and after 6, 12, 18, 24 and 52 weeks follow-up
Time Frame
after 52 weeks follow-up
Secondary Outcome Measure Information:
Title
Pain during functional tests
Description
During several functional tests, pain will be measured on a visual analogue scale, with 0 meaning no pain and 10 meaning unbearable pain, at baseline, 12 weeks and 24 weeks of follow-up.
Time Frame
after 12 weeks follow-up
Title
Pain during functional tests
Description
During several functional tests, pain will be measured on a visual analogue scale, with 0 meaning no pain and 10 meaning unbearable pain, at baseline, 12 weeks and 24 weeks of follow-up.
Time Frame
after 24 weeks follow-up
Title
Imaging methods
Description
Several imaging methods will be performed to identify the physiological parameter tendon structure shown in percentages healthy and damaged cells, at baseline, 12 weeks and 24 weeks of follow-up.
Time Frame
after 12 weeks follow-up
Title
Imaging methods
Description
Several imaging methods will be performed to identify the physiological parameter tendon structure shown in percentages healthy and damaged cells, at baseline, 12 weeks and 24 weeks of follow-up.
Time Frame
after 24 weeks follow-up
Title
Stiffness measurement
Description
The physiological parameter stiffness of the tendon will be measured in N/m, at baseline, 12 weeks and 24 weeks of follow-up.
Time Frame
after 12 weeks follow-up
Title
Stiffness measurement
Description
The physiological parameter stiffness of the tendon will be measured in N/m, at baseline, 12 weeks and 24 weeks of follow-up.
Time Frame
after 24 weeks follow-up
Title
Blood levels of amino acids
Description
Concentration of amino acids in blood will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Time Frame
after 12 weeks follow-up
Title
Blood levels of amino acids
Description
Concentration of amino acids in blood will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Time Frame
after 24 weeks follow-up
Title
Blood levels of inflammatory markers
Description
Concentration in blood of the inflammatory markers BSE and CRP will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Time Frame
after 12 weeks follow-up
Title
Blood levels of inflammatory markers
Description
Concentration in blood of the inflammatory markers BSE and CRP will be measured at baseline, 12 weeks and after 24 weeks of follow-up
Time Frame
after 24 weeks follow-up
Title
Dietary habits
Description
Dietary habits (nutritional intake) will be measured at the start and end of the intervention period using a diary.
Time Frame
baseline
Title
Dietary habits
Description
Dietary habits (nutritional intake) will be measured at the start and end of the intervention period using a diary.
Time Frame
after 24 weeks
Title
Compliance
Description
Data on the compliance with the exercise program and supplement intake, but also on training and competition load will be collected weekly using an online questionnaire
Time Frame
Weekly during the intervention, up to 24 weeks follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 16 - 40 years old (the chosen age range will minimize chances of other conditions causing anterior knee pain such as osteoarthritis among patients above 40 years and osteochondrotic diseases like Sinding-Larsen-Johansson syndrome and Osgood-Schlatter disease among patients below the age of 16). History of focal knee pain in patellar tendon or its patellar or tibial insertion in association with training and/or competition. Current symptom duration of at least 12 weeks. Sports participation at least once a week for at least one year. Palpation tenderness to the corresponding painful area on the patellar tendon. Focal patellar tendon pain during patellar tendon loading with a pain provocation test (single leg decline squat and/or single leg jump squat) Victorian Institute of Sports Assessment (VISA-P) score < 80 out of 100 points. Willingness to take (non-vegetarian) nutritional supplements. Exclusion Criteria: Known presence of inflammatory joint diseases (e.g. spondylarthropathy, gout or rheumatoid arthritis) or familial hypercholesterolaemia. Daily use of drugs with a putative effect on the patellar tendon in the preceding year (e.g. fluoroquinolones and statins) Knee surgery without a full completion of the rehabilitation program in the history of the index knee Previous patellar tendon rupture of the index knee Local injection therapy with corticosteroids, other drugs, blood, platelet rich plasma or stem cells in the preceding 12 months Acute knee injuries, including patellar tendon injuries with an acute onset Inability to perform the PTLE program Participation in other concomitant treatment programs Signs or symptoms of other coexisting knee pathology on physical examination (such as patellofemoral pain syndrome, joint effusion and joint line tenderness) or additional diagnostics when found necessary by the sports physician (Chondral lesion of the patella or trochlea on MRI or prepatellar bursitis on US). Already using collagen supplementation Giving blood donation in a period of two months prior to each test day Being pregnant or wish to become pregnant in the upcoming year Abuse of hard drugs An alcohol consumption >21 units/week (men) or >14 units/week (women)
Facility Information:
Facility Name
Gelderse Vallei Hospital
City
Ede
State/Province
Gelderland
ZIP/Postal Code
6716RP
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rieneke Terink, Dr
Phone
0031611172845
Email
rterink@zgv.nl
First Name & Middle Initial & Last Name & Degree
Johannes Zwerver, Prof
Phone
0031318434350
Email
jzwerver@zgv.nl
First Name & Middle Initial & Last Name & Degree
Lotte van Dam, Msc

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
patient data, not able to share

Learn more about this trial

Effect of Collagen/Vitamin C in Jumper's Knee; a RCT

We'll reach out to this number within 24 hrs